Levy Raphi sold $167K of DRTS
Levy Raphi (Chief Financial Officer) sold 17,500 shares of Alpha Tau Medical Ltd. (DRTS) at an average of $9.55 ($9.47–$10.00, $0.17M total) across 2 trades on 2026-06-23 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CFO’s open-market sale under a pre-arranged 10b5-1 plan is generally not a strong standalone bearish catalyst, but it can influence short-term sentiment and positioning.
Market read
Traders may monitor for additional scheduled 10b5-1 sales, but the article itself provides no new business or financial developments.
What to watch
The filing does not state remaining plan size, future scheduled sales, or any change in fundamentals—so the signal may be overstated.
Background
This is an SEC Form 4 insider transaction disclosure for Alpha Tau Medical Ltd. (DRTS).
Ticker impact
Alpha Tau Medical CFO Levy Raphi sold 17,500 shares in open-market transactions under a 10b5-1 plan, totaling $167,051.
Likely limited immediate price impact; any reaction would be modest unless accompanied by other company-specific news.
The filing is a primary-source Form 4 showing a planned open-market sale; there is no accompanying operational or financial catalyst in the text.
Market effects
No sector read-through provided; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerAlpha Tau Medical Ltd.
Company whose CFO insider sale is disclosed on Form 4.
- insiderLevy Raphi
Chief Financial Officer who sold 17,500 shares across two trades.
